The present disclosure relates to the field of bio-pharmacy, in particular, to an expression and/or overexpression vector, a pharmaceutical composition and a method for preparing the same. The expression and/or overexpression vector of the present disclosure includes a human glucokinase mutant-encoding gene and an adeno-associated virus vector. The pharmaceutical composition of the present disclosure includes virus particles obtained by packaging the expression and/or overexpression vector. After the pharmaceutical composition of the present disclosure is injected into an animal, an obvious expression and/or overexpression of a glucokinase mutant may occur, which has a good blood glucose level lowering effect, and provides a powerful new approach for controlling/stabilizing blood glucose level and/or preventing and treating glucose metabolism disorders, especially for preventing and treating diabetes.

Provided are a composition for producing tagatose, comprising fructose-6-phosphate 4-epimerase, and a method of producing tagatose using the same.

The present invention relates to an enzyme-catalyzed process for producing GDP- fucose from low-cost substrates guanosine and L-fucose or guanosine and D-Mannose in a single reaction mixture. Said process can be operated (semi)continuously or in batch mode. Further, said process can be adapted to produce fucosylated molecules and biomolecules including glycans, such as human milk oligosaccharides, proteins, peptides, glycoproteins or glycopeptides.

The invention is directed to a lactose-positive, galactose-negative, Streptococcus thermophilus strain releasing glucose during milk fermentation. This Streptococcus thermophilus strain carries mutation in the glcK gene, in the ccpA gene, in the lacZ gene and/or in the ptsH gene, and optionally in one or more genes, in particular one gene, encoding a protein of the mannose-glucose-specific PTS. The invention also concerns a composition comprising at least one, lactose-positive, galactose-negative, Streptococcus thermophilus strain of the invention, and the use of this strain or composition to manufacture a fermented dairy product.

The invention relates to a lactose-positive, galactose-negative, Streptococcus thermophilus strain carrying a mutation in 2 or 3 genes selected from the group consisting of 1) a gene encoding a protein of the mannose-glucose-specific PTS and a glcK gene, 2) a gene encoding a protein of the mannose-glucose-specific PTS and a ccpA gene, and 3) a gene encoding a protein of the mannose-glucose-specific PTS, a glcK gene and a ccpA gene, wherein said strain, when used to ferment milk, provides a low lactose fermented milk and/or a fermented milk not undergoing acidification when stored at fermentation temperature.

Provided are a composition for producing tagatose, comprising fructose-4-epimerase, and a method of producing tagatose using the same.

The present application relates to a psicose-6-phosphate phosphatase comprising motif A and motif B, a composition for producing D-psicose comprising the enzyme, and a method for producing D-psicose using the enzyme.

Provided are a composition for producing tagatose, comprising fructose-6-phosphate 4-epimerase, and a method of producing tagatose using the same.

A nanoplatelet serves as a substrate for immobilizing enzymes involved in consecutive reactions as a cascade. This results in a significant increase in the rate of catalysis as well as final product yield compared to non-immobilized enzymes or enzymes immobilized to quantum dots.

The present invention relates to a novel thermophilic and thermoresistant polyphosphate-dependent glucokinase having excellent stability, a composition comprising the same, and a method for producing glucose 6-phosphate using the same.